Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
Status:
Completed
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
The objective of this investigation is to assess safety and effectiveness of Xarelto under
practice routine use in VTE secondary prevention after acute DVT, focusing on
hemorrhagic-related AEs, recurrent venous thromboembolism (PE/DVT), all-cause mortality. This
study is a company sponsored, one- arm prospective cohort study with patients to whom
Rivaroxaban treatment for VTE (PE/DVT) has been chosen. The study includes a standard
observation period (1 year) and an extension survey period (2 years, at the longest).